DiaSorin, Tecan to Collaborate in New Platform Development
DiaSorin and Tecan Group have announced that they have agreed to collaborate in a development under which DiaSorin will make use of Tecan’s Fluent® Laboratory Automation Solution as its nucleic acid extraction platform. The new platform will be used in combination with the DiaSorin Liaison® MDX PCR system to provide the customer with a complete sample to result system for molecular diagnostics.
The Fluent platform, to be supplied through Tecan Partnering, will be optimized for use with DiaSorin extraction chemistry and automated PCR set up of the Liaison MDX 96-well disc. Fluent breaks new ground, delivering more capacity and increased speed. The platform provides exceptional precision, throughput and walkaway time.
Dr David Martyr, CEO of Tecan, commented: “We are delighted that DiaSorin has chosen the Fluent Laboratory Automation Solution as the basis for this new platform. The precision, speed and low volume liquid handling accuracy offered by the Fluent are ideal for molecular diagnostics applications.”
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE